Aerpio Pharmaceuticals (Aerpio Pharmaceuticals) Cash Conversion Cycle : 0.00 (As of Jun. 2021)

View and export this data going back to 2017. Start your Free Trial

What is Aerpio Pharmaceuticals Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Aerpio Pharmaceuticals's Days Sales Outstanding for the three months ended in Jun. 2021 was 0.
Aerpio Pharmaceuticals's Days Inventory for the three months ended in Jun. 2021 was .
Aerpio Pharmaceuticals's Days Payable for the three months ended in Jun. 2021 was .
Therefore, Aerpio Pharmaceuticals's Cash Conversion Cycle (CCC) for the three months ended in Jun. 2021 was 0.00.

Aerpio Pharmaceuticals Cash Conversion Cycle Historical Data

The historical data trend for Aerpio Pharmaceuticals's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aerpio Pharmaceuticals Cash Conversion Cycle Chart

Aerpio Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Cash Conversion Cycle

Get a 7-Day Free Trial

Aerpio Pharmaceuticals Quarterly Data
	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21
Cash Conversion Cycle	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Aerpio Pharmaceuticals's Cash Conversion Cycle

For the Biotechnology subindustry, Aerpio Pharmaceuticals's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aerpio Pharmaceuticals's Cash Conversion Cycle Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aerpio Pharmaceuticals's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Aerpio Pharmaceuticals's Cash Conversion Cycle falls into.

Aerpio Pharmaceuticals Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Aerpio Pharmaceuticals's Cash Conversion Cycle for the fiscal year that ended in Dec. 2020 is calculated as

Cash Conversion Cycle	=	Days Sales Outstanding	+	Days Inventory	-	Days Payable
	=	0	+		-
	=	0.00

Aerpio Pharmaceuticals's Cash Conversion Cycle for the quarter that ended in Jun. 2021 is calculated as:

Cash Conversion Cycle	=	Days Sales Outstanding	+	Days Inventory	-	Days Payable
	=	0	+		-
	=	0.00

Aerpio Pharmaceuticals (NAS:ARPO) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.

Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.

Aerpio Pharmaceuticals Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Aerpio Pharmaceuticals's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.

Aerpio Pharmaceuticals (Aerpio Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aerpio Pharmaceuticals Inc (NAS:ARPO) » Definitions » Cash Conversion Cycle

Comparable Companies

Traded in Other Exchanges

N/A

Address

9987 Carver Road, Cincinnati, OH, USA, 45242

Website

https://www.aerpio.com

Aerpio Pharmaceuticals Inc is a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases. The company's product razuprotafib is a small molecule Tie2 activator being developed for the topical ocular treatment of primary open-angle glaucoma. Other products under the pipeline are ARP-1536 and AKB-4924.

Executives

Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Pravin Dugel	director	C/O AERPIO PHARMACEUTICALS, INC., 9987 CARVER ROAD, CINCINNATI OH 45242
Caley Castelein	director	THOM. WEISEL HEALTHCARE VENTURES, ONE MONTGOMERY STREET, SAN FRANCISCO CA 94104
Anupam Dalal	director	88 KEARNY STREET, SUITE 1800, SAN FRANCISCO CA 94108
Cheryl Cohen	director	C/O MEDIVATION, INC., 201 SPEAR ST., 3RD FLOOR, SAN FRANCISCO CA 94105
Steven Prelack	director	7 WHEELWRIGHT ROAD, MEDFIELD MA 02052
Regina Marek	officer: Vice President of Finance	C/O AERPIO PHARMACEUTICALS, INC., 9987 CARVER ROAD, SUITE 420, CINCINNATI OH 45242
Joseph H. Gardner	director, officer: President	C/O AERPIO PHARMACEUTICALS, INC., 9987 CARVER ROAD, CINCINNATI OH 45242
Kevin G. Peters	officer: See Remarks	C/O AERPIO PHARMACEUTICALS, INC., 9987 CARVER ROAD, C OH 45242
Muneer A Satter	director, 10 percent owner	C/O SATTER INVESTMENT MANAGEMENT, LLC, 676 NORTH MICHIGAN AVENUE, SUITE 4000, CHICAGO IL 60611
Chau Quang Khuong	director, 10 percent owner	C/O ORBIMED ADVISORS, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Michael W Rogers	officer: See Remarks	C/O KERYX BIOPHARMACEUTICALS INC, ONE MARINA PARK DRIVE, BOSTON MA 02210
Stephen J Hoffman	director, officer: Chief Executive Officer	C/O SKYLINE VENTURES, 525 UNIVERSITY AVE., SUITE 1350, PALO ALTO CA 94301
Novartis Bioventures Ltd	10 percent owner	C/O NOVARTIS INTERNATIONAL AG, WSJ-200.220, CH-4002 BASEL V8 0000000000
Ag Novartis	10 percent owner	LICHTSTRASSE 35, BASEL V8 CH 4056